公开(公告)号：US20100093751A1

公开(公告)日：2010-04-15

申请号：US12520004

申请日：2007-12-13

申请人： George Hynd ,  John Gary Montana ,  Harry Finch ,  Trevor Harrison ,  Janusz Kulagowski

发明人： George Hynd ,  John Gary Montana ,  Harry Finch ,  Trevor Harrison ,  Janusz Kulagowski

IPC分类号： A61K31/437 ,  C07D471/04 ,  A61K31/496 ,  A61K31/506 ,  A61P11/00 ,  A61P11/06 ,  A61P17/06 ,  A61P1/00

CPC分类号： C07D471/04

摘要： Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, inter alia, respiratory diseases: wherein R1 is fluoro, chloro, cyano or trifluoromethyl; R2 is hydrogen, fluoro or chloro; R3 is hydrogen, fluoro, chloro or trifluoromethyl; X is —CH2—, —S—, —S(═O)— or —S(═O)2—; one of Y and Y1 is hydrogen and the other is —C(═O)R4, or —S(═O)2R4, or —CR5R6OR7 or a heterocyclic group selected from furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, furazanyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,4-triazinyl and 1,3,5-triazinyl any of which may be optionally substituted; R4 is an optionally substituted cyclic amino group having 5, 6 or 7 ring atoms which is linked to the carbonyl or sulfonyl through a ring nitrogen; R5 and R6 are independently hydrogen, (C1C3)alkyl, cyclopropyl, or R5 and R6 taken together with the carbon atom to which they are attached form a 3-6 membered cycloalkyl ring; and R7 is optionally substituted (C1-C6)alkyl or (C3-C6)cycloalkyl,

摘要翻译： 式（I）化合物是CRTH2配体，可用于治疗呼吸系统疾病，其中R1是氟，氯，氰基或三氟甲基; R2是氢，氟或氯; R3是氢，氟，氯或三氟甲基; X是-CH 2 - ， - S - ， - S（= O） - 或-S（= O）2 - ; Y和Y1之一是氢，另一个是-C（= O）R 4或-S（= O）2 R 4或-CR 5 R 6 OR 7或选自呋喃基，噻吩基，吡咯基，恶唑基，噻唑基，咪唑基，吡唑基 ，异恶唑基，异噻唑基，1,2,3-恶二唑基，1,2,4-恶二唑基，1,3,4-恶二唑基，1,2,5-恶二唑基，呋咱基，1,2,3-三唑基，1,2 ，4-三唑基，1,2,3-噻二唑基，1,2,5-噻二唑基，1,3,4-噻二唑基，1,2,4-噻二唑基，四唑基，吡啶基，哒嗪基，嘧啶基，吡嗪基，1,2 ，4-三嗪基和1,3,5-三嗪基，其中任何一个可以是任选取代的; R4是具有5,6或7个环原子的任选取代的环状氨基，其通过环氮连接到羰基或磺酰基; R5和R6独立地为氢，（C1C3）烷基，环丙基或R5和R6与它们所连接的碳原子一起形成3-6元环烷基环; 并且R 7是任选取代的（C 1 -C 6）烷基或（C 3 -C 6）环烷基，

公开(公告)号：US07528157B2

公开(公告)日：2009-05-05

申请号：US11615024

申请日：2006-12-22

申请人： Alexander W. Oxford ,  Richard J. Davis ,  Robert A. Coleman ,  Kenneth L. Clark ,  David E. Clark ,  Neil V. Harris ,  Garry Fenton ,  George Hynd ,  Keith A. J. Stuttle ,  Jonathan M. Sutton ,  Christopher G. Newton

发明人： Alexander W. Oxford ,  Richard J. Davis ,  Robert A. Coleman ,  Kenneth L. Clark ,  David E. Clark ,  Neil V. Harris ,  Garry Fenton ,  George Hynd ,  Keith A. J. Stuttle ,  Jonathan M. Sutton ,  Christopher G. Newton

IPC分类号： C07D307/68 ,  C07D405/10 ,  A61K31/34 ,  A61K31/443

CPC分类号： C07D307/54 ,  A61K31/34 ,  A61K31/341 ,  A61K31/4155 ,  A61K31/443 ,  C07D307/64 ,  C07D307/68 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

摘要： Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either —(CH2)n—X—, where n is 1 or 2 and X is O, S, S(═O), S(═O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is —C(═O)NRN2—, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; (iv) tetrazol-5-yl.

摘要翻译： 式（I）化合物：其中：R2是H或任选取代的C 1-4烷基; Y是 - （CH 2）n X-，其中n是1或2，X是O，S，S（-O），S（-O）2或NRN1，其中RN1选自H或任选取代的C1- 4烷基或Y是-C（-O）NRN 2 - ，其中RN 2选自H，和任选取代的C 1-7烷基或C 5-20芳基; R3是与另外任意取代的C 6芳基连接的任意取代的C6芳基，其中如果两个C 6芳基都是苯环，则两个环之间可能有一个氧桥，与两个环上的连接相邻; A是单键或C1-3亚烷基; 并且R 5是：（i）羧基; （ii）式（II）的基团：（iii）式（III）的基团：其中R是任选取代的C 1-7烷基，C 5-20芳基或NRN 3 R N 4，其中RN 3和RN 4独立地选自任选取代的C 1 -4-烷基; （ⅳ）四唑-5-基。

公开(公告)号：US07417068B2

公开(公告)日：2008-08-26

申请号：US10964831

申请日：2004-10-15

申请人： David Edward Clark ,  Neil Victor Harris ,  Garry Fenton ,  George Hynd ,  Keith Alfred James Stuttle ,  Jonathan Mark Sutton ,  Alexander William Oxford ,  Richard Jon Davis ,  Robert Alexander Coleman ,  Kenneth Lyle Clark

发明人： David Edward Clark ,  Neil Victor Harris ,  Garry Fenton ,  George Hynd ,  Keith Alfred James Stuttle ,  Jonathan Mark Sutton ,  Alexander William Oxford ,  Richard Jon Davis ,  Robert Alexander Coleman ,  Kenneth Lyle Clark

IPC分类号： A61K31/341 ,  C07D307/34

CPC分类号： C07D307/68

摘要： A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein one of R2 and R5 is: (i) H or an optionally substituted C1-4 alkyl group; or (ii)an optionally substituted C5-7 aryl; and the other of R2 and R5 is the other group; m and n can be 0 or 1, and m+n=1 or 2 RN is H or optionally substituted C1-4 alkyl R3 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl, or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; or (iv) tetrazol-5-yl.

摘要翻译： 式（I）化合物或其盐，溶剂合物和化学保护形式，其中R 2和R 5中的一个为：（i）H或任选地 取代的C 1-4烷基; 或（ii）任选取代的C 5-7芳基; R 2和R 5中的另一个是另一个基团; m和n可以是0或1，m + n = 1或2 R N是H或任选取代的C 1-4烷基R 3， SUP>是：（i）羧基; （ii）式（II）的基团：（iii）式（III）的基团：其中R是任选取代的C 1-7烷基，C 5〜20 其中R 3，N 3和R 4各自独立地选自任选取代的C 1 -C 6芳基或NR N 3 N， 1-4个C 1-4烷基; 或（iv）四唑-5-基。

公开(公告)号：US07326732B2

公开(公告)日：2008-02-05

申请号：US11055724

申请日：2005-02-11

申请人： Alexander William Oxford ,  Richard Jon Davis ,  Robert Alexander Coleman ,  Kenneth Lyle Clark ,  David Edward Clark ,  Neil Victor Harris ,  Garry Fenton ,  George Hynd ,  Keith Alfred James Stuttle ,  Jonathan Mark Sutton ,  Mark Richard Ashton ,  Edward Andrew Boyd ,  Shirley Ann Brunton

发明人： Alexander William Oxford ,  Richard Jon Davis ,  Robert Alexander Coleman ,  Kenneth Lyle Clark ,  David Edward Clark ,  Neil Victor Harris ,  Garry Fenton ,  George Hynd ,  Keith Alfred James Stuttle ,  Jonathan Mark Sutton ,  Mark Richard Ashton ,  Edward Andrew Boyd ,  Shirley Ann Brunton

IPC分类号： C07C233/65 ,  C07D257/04 ,  A61K31/41 ,  A61K31/164

CPC分类号： C07D213/81 ,  C07C233/75 ,  C07C233/81 ,  C07C235/84 ,  C07D233/90 ,  C07D257/04 ,  C07D277/24 ,  C07D277/26 ,  C07D277/56 ,  C07D307/46 ,  C07D307/68 ,  C07D307/91 ,  C07D333/38 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/12

摘要： A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN′ is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and the other of RP3 and RP4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally when RP3 is —Cm alkylene-R2, m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R2 is tetrazol-5-yl, m+n may be 0; or where one of RP3 and RP4 is —O—CH2—R2, and the other of RP3 and RP4 is H, n is 0; RN is H or optionally substituted C1-4 alkyl; R2 is either: —CO2H (carboxy); —CONH2; —CH2—OH; or tetrazol-5-yl.

公开(公告)号：US20070123575A1

公开(公告)日：2007-05-31

申请号：US11615024

申请日：2006-12-22

申请人： Alexander Oxford ,  Richard Davis ,  Robert Coleman ,  Kenneth Clark ,  David Clark ,  Neil Harris ,  Garry Fenton ,  George Hynd ,  Keith Stuttle ,  Jonathan Sutton ,  Christopher Newton

发明人： Alexander Oxford ,  Richard Davis ,  Robert Coleman ,  Kenneth Clark ,  David Clark ,  Neil Harris ,  Garry Fenton ,  George Hynd ,  Keith Stuttle ,  Jonathan Sutton ,  Christopher Newton

IPC分类号： A61K31/41 ,  A61K31/34 ,  C07D405/02

CPC分类号： C07D307/54 ,  A61K31/34 ,  A61K31/341 ,  A61K31/4155 ,  A61K31/443 ,  C07D307/64 ,  C07D307/68 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

摘要： Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either —(CH2)n—X—, where n is 1 or 2 and X is O, S, S(═O), S(═O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is —C(═O)NRN2—, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): ; or (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; (iv) tetrazol-5-yl.

摘要翻译： 式（I）的化合物：其中：R 2是H或任选取代的C 1-4烷基; Y是 - （CH 2）n -X-，其中n是1或2，X是O，S，S（-O），S（-O ）N 2，或NR 11，其中R 0,1选自H或任选取代的C 1-4烷基 ，或Y是-C（-O）NR N2 - ，其中R N2选自H和任选取代的C 1-7 - 烷基或C 5-20-20芳基; R 3是与另外任选取代的C 6 -C 6芳基连接的任选取代的C 6-14芳基，其中如果两个C 6 芳基是苯环，两个环之间可能有一个氧桥，与两个环上的连接相邻; A是单键或C 1-3-3亚烷基; 和R 5是：（i）羧基; （ii）式（II）的组： 或（iii）式（III）的基团：其中R是任选取代的C 1-7烷基，C 5-20-20芳基或NR N 3， 其中R“N 3”和“R”N 4“独立地选自任选取代的C 1-4烷基 ; （ⅳ）四唑-5-基。

公开(公告)号：US20050256170A1

公开(公告)日：2005-11-17

申请号：US11055724

申请日：2005-02-11

申请人： Alexander Oxford ,  Richard Davis ,  Robert Coleman ,  Kenneth Clark ,  David Clark ,  Neil Harris ,  Garry Fenton ,  George Hynd ,  Keith Stuttle ,  Jonathan Sutton ,  Mark Ashton ,  Edward Boyd ,  Shirley Brunton

发明人： Alexander Oxford ,  Richard Davis ,  Robert Coleman ,  Kenneth Clark ,  David Clark ,  Neil Harris ,  Garry Fenton ,  George Hynd ,  Keith Stuttle ,  Jonathan Sutton ,  Mark Ashton ,  Edward Boyd ,  Shirley Brunton

IPC分类号： A61K31/4178 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  C07C233/75 ,  C07C233/81 ,  C07C235/84 ,  C07D213/81 ,  C07D233/90 ,  C07D257/04 ,  C07D277/24 ,  C07D277/26 ,  C07D277/56 ,  C07D307/46 ,  C07D307/68 ,  C07D307/91 ,  C07D333/38 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/12 ,  C07D413/02 ,  C07D417/02 ,  C07D43/02

CPC分类号： C07D213/81 ,  C07C233/75 ,  C07C233/81 ,  C07C235/84 ,  C07D233/90 ,  C07D257/04 ,  C07D277/24 ,  C07D277/26 ,  C07D277/56 ,  C07D307/46 ,  C07D307/68 ,  C07D307/91 ,  C07D333/38 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/12

摘要： A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisiting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O., and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN′ is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and the other of RP3 and RP4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally when RP3 is —Cm alkylene-R2, m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R2 is tetrazol-5-yl, m+n may be 0; or where one of RP3 and RP4 is —O—CH2—R2, and the other of RP3 and RP4 is H, n is 0; RN is H or optionally substituted C1-4 alkyl; R2 is either: —CO2H (carboxy); —CONH2; —CH2-OH; or tetrazol-5-yl.

公开(公告)号：US08080567B2

公开(公告)日：2011-12-20

申请号：US12063421

申请日：2006-08-09

申请人： Alexander William Oxford ,  Richard Jon Davis ,  Robert Alexander Coleman ,  Kenneth Lyle Clark ,  David Edward Clark ,  Shirley Ann Brunton ,  Neil Victor Harris ,  Garry Fenton ,  George Hynd ,  Keith Alfred James Stuttle ,  Jonathan Mark Sutton ,  Mark Richard Ashton ,  Edward Andrew Boyd

发明人： Alexander William Oxford ,  Richard Jon Davis ,  Robert Alexander Coleman ,  Kenneth Lyle Clark ,  David Edward Clark ,  Shirley Ann Brunton ,  Neil Victor Harris ,  Garry Fenton ,  George Hynd ,  Keith Alfred James Stuttle ,  Jonathan Mark Sutton ,  Mark Richard Ashton ,  Edward Andrew Boyd

IPC分类号： A61K31/44 ,  A61K31/42 ,  A61K31/195

CPC分类号： C07C233/81 ,  C07C257/18 ,  C07D213/70 ,  C07D263/57 ,  C07D307/42 ,  C07D307/54 ,  C07D307/68 ,  C07D307/91 ,  C07D405/12

摘要： A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the group consisting of: formula (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formula (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formula (A) (B) where RP6 is selected from fluoro and chloro; and R2 is either: (i) —CO2H; (ii) —CONH2; (iii) —CH2—OH; or (iv) tetrazol-5-yl.

摘要翻译： 式（III）化合物或其盐，溶剂化物和化学保护形式，其中：R 5为任选取代的C 5-20芳基或C 4-20烷基; L'是单键，-O-或-C（= O） - ; A选自：式（i）（ii）（iii）其中X和Y选自：O和CR 3; S和CR3; NH和CR3; NH和N; O和N; S和N; N和S; 和N和O，并且其中虚线表示适当位置的双键，并且其中Q为N或CH; D选自：式（i）（ii）（iii）（iv）（v）（vii）（viii）（ix）B选自：其中选择RP6的式（A）（B） 来自氟和氯; 并且R2是：（i）-CO 2 H; （ii）-CONH 2; （ⅲ）-CH 2 -OH; 或（iv）四唑-5-基。

公开(公告)号：US07803841B2

公开(公告)日：2010-09-28

申请号：US12346516

申请日：2008-12-30

申请人： Alexander William Oxford ,  Richard Jon Davis ,  Robert Alexander Coleman ,  Kenneth Lyle Clark ,  David Edward Clark ,  Neil Victor Harris ,  Garry Fenton ,  George Hynd ,  Keith Alfred James Stuttle ,  Jonathan Mark Sutton ,  Mark Richard Ashton ,  Edward Andrew Boyd ,  Shirley Ann Brunton

发明人： Alexander William Oxford ,  Richard Jon Davis ,  Robert Alexander Coleman ,  Kenneth Lyle Clark ,  David Edward Clark ,  Neil Victor Harris ,  Garry Fenton ,  George Hynd ,  Keith Alfred James Stuttle ,  Jonathan Mark Sutton ,  Mark Richard Ashton ,  Edward Andrew Boyd ,  Shirley Ann Brunton

IPC分类号： A61K31/166 ,  C07C233/65

CPC分类号： C07D213/81 ,  C07C233/75 ,  C07C233/81 ,  C07C235/84 ,  C07D233/90 ,  C07D257/04 ,  C07D277/24 ,  C07D277/26 ,  C07D277/56 ,  C07D307/46 ,  C07D307/68 ,  C07D307/91 ,  C07D333/38 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/12

摘要： The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor.

摘要翻译： 本公开提供EP2受体激动剂化合物和使用该化合物治疗可通过EP2受体激动作用缓解的病症的方法。

公开(公告)号：US20100144787A1

公开(公告)日：2010-06-10

申请号：US12531935

申请日：2008-04-03

申请人： John Gary Montana ,  Harry Finch ,  George Hynd ,  Michael Colin Cramp ,  Rosa Arienzo ,  Neville McLean

发明人： John Gary Montana ,  Harry Finch ,  George Hynd ,  Michael Colin Cramp ,  Rosa Arienzo ,  Neville McLean

IPC分类号： A61K31/4709 ,  C07D215/233 ,  C07D215/227 ,  C07D215/12 ,  A61P11/06 ,  A61P11/08 ,  A61P11/16 ,  A61P11/02

CPC分类号： C07D401/10 ,  C07D215/227 ,  C07D215/233 ,  C07D413/10 ,  C07D417/10

摘要： Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1C6 alkyl or C3-C6 cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(═O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.

摘要翻译： 式（I）化合物是可用于治疗例如哮喘和COPD的CRTH2配体，其中：R1是卤素或氰基; R2是氢或甲基; R 3和R 4独立地为-OR 6，C 1 -C 6烷基或C 3 -C 6环烷基，后两个基团任选被一个或多个卤素原子取代; R5是氢或卤素; R6是C1C6烷基或C3-C6环烷基，其任一个任选被一个或多个卤素原子取代; X是-CH 2 - ， - S-或-O-; Y和Y1中的一个是氢，另一个是选自本说明书中提到的那些的OR 6，-C（= O）R 7，NR 8 SO 2 R 6或杂环基; R6，R7和R8如说明书中所定义。

公开(公告)号：US20100144786A1

公开(公告)日：2010-06-10

申请号：US12531367

申请日：2007-03-29

申请人： Michael Colin Cramp ,  Rosa Arienzo ,  George Hynd ,  Peter Crackett ,  Yann Griffon ,  Trevor Keith Harrison ,  Nicholas Charles Ray ,  Harry Finch ,  John Gary Montana

发明人： Michael Colin Cramp ,  Rosa Arienzo ,  George Hynd ,  Peter Crackett ,  Yann Griffon ,  Trevor Keith Harrison ,  Nicholas Charles Ray ,  Harry Finch ,  John Gary Montana

IPC分类号： A61K31/47 ,  C07D215/233 ,  A61P17/02 ,  A61P11/06 ,  A61P37/06 ,  A61P17/06

CPC分类号： C07D215/233 ,  C07D215/20 ,  C07D215/227

摘要： Specific quinoline derivatives are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory component.

摘要翻译： 特定的喹啉衍生物是可用于治疗具有炎性成分的病症的CRTH2拮抗剂。